medigraphic.com
Colegio de Medicina Interna de México.

2020, Number 3

<< Back Next >>

Med Int Mex 2020; 36 (3)

New perspectives for the ambulatory or early treatment of COVID-19

Zúñiga-Blanco BL, Pruneda-Álvarez LG, Enríquez-Macías ML, Fyda J

Language: Spanish
References: 49
Page: 323-331
PDF size: 244.42 Kb.


ABSTRACT

In December 2019, a novel coronavirus known as SARS-CoV-2, emerged in Wuhan, China, causing the respiratory illness COVID-19. The WHO declared COVID-19 as Pandemic on March 12th, 2020. Therefore, the global public health authorities, research and medical communities have relied on quarantine, isolation, instauring adequate diagnosis and on supportive care for those who become ill, in order to decrease the severity of COVID-19. Regardless of these infection-control measures, to prevent the spread of the disease, the transmission of this virus is exponentially growing, hence, we require a specific antiviral agent. Until April 7, 2020, according to the WHO, there are globally more than 1,300,000 confirmed cases of COVID-19 and nearly 72,000 deaths. In Mexico, we are facing 2439 cases and 125 deaths and rising. Therefore, it is urgent to treat the infected and optimally decrease viral shedding and subsequent transmission of SARS-CoV-2. Scientists around the world are endeavoring to find specific antivirals for the virus. Several drugs such as Chloroquine, Hidroxicloroquine, Azithromycin, Interferon a, Ribavirin, Remdesivir, Favipiravir, Teicoplanin, Melatonin and Imitinab are currently undergoing clinical studies to test their efficacy and safety in the treatment of COVID-2019.


REFERENCES

  1. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV Spike in the prefusion conformation. Science 2020, eabb2507.

  2. Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 Mar 11. Pii: S0140- 6736(20)30566-3. doi: 10.1016/S0140-6736(20)30566-3.

  3. Marco Cascella, Micael Rajnik, Arturo Cuomo, Raffaela Di Napoli Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan- 2020 Mar 8.

  4. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 Feb 24. DOI: 10.1001/jama.2020.2648.

  5. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV - A target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7(3):226-236. DOI: 10.1038/nrmicro2090.

  6. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. SARS-CoV-2 cell entry fepends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020. DOI: 10.1016/j.cell.2020.02.052.

  7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet 2020;395:497- 506. https://doi.org/10.1016/S0140-6736(20)30183-5.

  8. Liu Cynthia, Li Yingzhu, Lin, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human Coronavirus diseases. ACS Cent Scl March, 2020. https://doi.org/10.1016/S0140-6736(20)30183-5.

  9. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio DOI: 10.1128/mBio.00221-18.

  10. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020;30:269-271. https://doi.org/10.1038/s41422-020-0282-0.

  11. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Comm 2020;11:222-222. DOI: 10.1038/s41467-019-13940-6.

  12. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2001282.

  13. Li Y, Chen M, Cao H, Zhu Y, Zheng J, Zhou H. Extraordinary GU-rich single-strand ARN identified from SARS coronavirus contributes an excessive innate immune response. Microbes Infect 2013;15:88-95. DOI: 10.1016/j. micinf.2012.10.008.

  14. Xiaoling Xu, Mingfeng Han, Tiantian Li, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv:202003.00026v1.

  15. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol 2016;90:8924-8933. DOI: 10.1128/JVI.01429-16.

  16. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J. Baricitinib as potential treatment for 2019- nCoV acute respiratory disease. Lancet 2020;395(10223):e30-e31. DOI:https://doi.org/10.1016/ S0140-6736(20)30304-4.

  17. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet February 2006;6:67-96. DOI: 10.1016/S1473- 3099(06)70361-9.

  18. Yiwu Yan, Zhen Zou, Yang Sun, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Research 2013;23:300-302. DOI: 10.1038/cr.2012.165.

  19. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV2. Int J Antimicrob Agents 2020 Feb 15:105923. doi: 10.1016/j.ijantimicag.2020.105923.

  20. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020 Feb 19. DOI: 10.5582/bst.2020.01047.

  21. Danza A, Graña D, Goñi M, Vargas A, Ruiz-Irastorza G. Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas. Rev Med Chile 2016;144:232-240. http://dx.doi.org/10.4067/S0034-98872016000200012.

  22. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; (published online March 9) https://doi.org/10.1093/cid/ciaa237.

  23. Danza A, Díaz L, Ruiz-Irastorza G. Hidroxicloroquina en el embarazo y la lactancia. Rev Med Urug 2015;31(2):128-32.

  24. Zarogoulidis P, et al. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012;68:479-503. DOI: 10.1007/s00228-011-1161-x.

  25. Balloy V, et al. Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge. Br J Pharmacol 2014;171:1783-1794. DOI: 10.1111/bph.12574.

  26. Wolter J, et al. Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-216. DOI: 10.1136/ thorax.57.3.212.

  27. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004;54:21-28. DOI: 10.1093/jac/dkh309.

  28. Wong C, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380:660-667. DOI: 10.1016/S0140-6736(12)60953-2.

  29. Bosseboeuf E, Aubry M, Nhan T, de Pina, JJ, Rolain JM, Raoult D, et al. Azithromycin inhibits the replication of Zika virus. J Antivirals Antiretrovirals 2018;10(1):6-11. doi: 10.4172/1948-5964.1000173.

  30. Gautret, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label nonrandomized clinical trial. Int J Antimicrob Agents. March 17 2020. DOI:10.1016/j.ijantimicag.2020.105949.

  31. Gautret, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. Preprint.

  32. Baron SA, Devaux C, Rolain JM, Raoult D, Colson P. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?. Int J Antimicrob Agents 2020. DOI: 10.1016/j. ijantimicag.2020.105944.

  33. Guangdi Li, Erik De Clercq. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 2020;19:149-150.

  34. Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. BioRxiv 2020:2020.02.05.935387.

  35. Armenia I, Marcone GL, Berini F, Orlandi VT, Pirrone C, Martegani E, Gornati R, Bernardini G, Marinelli F. Magne tic nanoconjugated teicoplanin: A novel tool for bacterial infection site targeting. Front Microbiol 2018;9:2270. doi: 10.3389/fmicb.2018.02270.

  36. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.

  37. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging ARN viruses. Antiviral Res 2018;153:85-94. DOI: 10.1016/j. antiviral.2018.03.003.

  38. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad-spectrum inhibitor of viral ARN polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:449-463. DOI: 10.2183/ pjab.93.027.

  39. Chang Chen, Jianying Huang, Zhenshun Cheng, Jianyuan Wu, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. https://doi.org/10.1101/2020.03.1 7.20037432.

  40. Zhang R, Wang X, Ni L, et al. COVID19: Melatonin as a potential adjuvant treatment. LifeSciences 2018. https:// doi.org/10.1016/j.lfs.2020.117583.

  41. Reiter RJ, Ma Q, Sharma T. Treatment of Ebola and other infectious diseases: melatonin “goes viral”. Melatonin Res 2020;3:43-57. DOI: 10.32794/mr11250047.

  42. Boga JA, Coto-Montes A, Rosales-Corral SA, Tan DX, Reiter RJ. Beneficial actions of melatonin in the management of viral infections: a new use for this “molecular handyman”? Rev Med Virol 2012;22:323-338. DOI: 10.1002/rmv.1714.

  43. Ben-Nathan D, Maestroni GJ, Lustig S, Conti A. Protective effects of melatonin in mice infected with encephalitis viruses. Arch Virol 1995;140:223-230. DOI: 10.1007/bf01309858.

  44. FDA Website: https://www.fda.gov/vaccines-blood-biologics/ Investigational-new-drug-ind-ordevice-exemption-ideprocess- cber/investigational-covid-19-convalescent-plasmaemergency- inds?utm_campaign=What%27sNew2020- 03-24&utm_medium=email&utm_source=Eloqua.

  45. Guangyu Zhou, Qi Zhao. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci 2020;16. DOI: 10.7150/ijbs.45123.

  46. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA March 27, 2020. doi:10.1001/jama.2020.4783.

  47. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020;138003. DOI: 10.1172/JCI138003.

  48. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24:44-46. DOI: 10.1007/s10096- 004-1271-9.

  49. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:748-754. DOI: 10.1001/jama.285.6.748.




2020     |     www.medigraphic.com